Blue Plus

BluePlus is a clinical-stage biotechnology company headquartered in Shanghai, China, dedicated to the research and development of innovative ophthalmic therapies. The company primarily focuses on adeno-associated virus (AAV) mediated gene therapies and advanced medical devices for treating chronic retinal diseases. Its lead program, BP-001, is an investigational gene therapy targeting wet age-related macular degeneration (wAMD) by delivering a transgene that expresses an anti-VEGF protein. By leveraging its proprietary platform, BluePlus aims to reduce the treatment burden for patients who currently require frequent intravitreal injections. The company is expanding its pipeline to include treatments for inherited retinal diseases and other vision-threatening conditions.